VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Comparison

Measles Virus Vaccine VVM Measles Virus Vaccine VVN Measles Virus Vaccine VVP
Vaccine Information Vaccine Information Vaccine Information
  • Vaccine Ontology ID: VO_0011537
  • Type: Recombinant vector vaccine
  • Status: Research
  • M matrix protein gene engineering:
    • Type: Recombinant vector construction
    • Detailed Gene Information: Click Here.
  • Vector: Vaccinia Virus (Brinckmann et al., 1991).
  • Immunization Route: Intraperitoneal injection (i.p.)
  • Vaccine Ontology ID: VO_0011535
  • Type: Recombinant vector vaccine
  • Status: Research
  • N nucleocapsid protein gene engineering:
    • Type: Recombinant vector construction
    • Detailed Gene Information: Click Here.
  • Vector: Vaccinia virus (Brinckmann et al., 1991).
  • Immunization Route: Intraperitoneal injection (i.p.)
  • Vaccine Ontology ID: VO_0011536
  • Type: Recombinant vector vaccine
  • Status: Research
  • P phosphoprotein gene engineering:
    • Type: Recombinant vector construction
    • Detailed Gene Information: Click Here.
  • Vector: Vaccinia virus (Brinckmann et al., 1991).
  • Immunization Route: Intraperitoneal injection (i.p.)
Host Response Host Response Host Response

Rat Response

  • Host Strain: Lewis
  • Vaccination Protocol: To determine the protective effect of individual measles virus (MV) proteins, 2- to 3-week-old suckling rats were immunized either once, twice or three times at 5 to 7 day intervals by i.p. injections of 107 p.f.u, of recombinant vaccinia virus (VV) expressing individual structural proteins or VV-wt (Brinckmann et al., 1991).
  • Challenge Protocol: Three to 5 days after the last recombinant VV injection, the animals were challenged by intracerebral (i.c.) infection with the neurotropic rat brain-adapted MV strain CAM/RBH (0.5 × 104 to 8 x 10 ~ TCID50) (Brinckmann et al., 1991).
  • Efficacy: Lewis rats were immunized with recombinant vaccinia virus (VV) expressing various proteins of measles virus (MV). VVM (Matrix Protein) -immunized rats were partially protected from MV challenge (Brinckmann et al., 1991).

Rat Response

  • Host Strain: Lewis
  • Vaccination Protocol: To determine the protective effect of individual measles virus (MV) proteins, 2- to 3-week-old suckling rats were immunized either once, twice or three
    times at 5 to 7 day intervals by i.p. injections of 107 p.f.u, of recombinant vaccinia virus (VV) expressing individual structural proteins or VV-wt (Brinckmann et al., 1991).
  • Challenge Protocol: Three to 5 days after the last recombinant VV injection, the animals were challenged by intracerebral (i.c.) infection with the neurotropic rat brain-adapted MV strain CAM/RBH (0.5 × 104 to 8 x 10 ~ TCID50) (Brinckmann et al., 1991).
  • Efficacy: Rats immunized with recombinant VVN survived a MV challenge infection (Brinckmann et al., 1991).

Rat Response

  • Host Strain: Lewis
  • Vaccination Protocol: To determine the protective effect of individual measles virus (MV) proteins, 2- to 3-week-old suckling rats were immunized either once, twice or three times at 5 to 7 day intervals by i.p. injections of 107 p.f.u, of recombinant vaccinia virus (VV) expressing individual structural proteins or VV-wt (Brinckmann et al., 1991).
  • Challenge Protocol: Three to 5 days after the last recombinant VV injection, the animals were challenged by intracerebral (i.c.) infection with the neurotropic rat brain-adapted MV strain CAM/RBH (0.5 × 104 to 8 x 10 ~ TCID50) (Brinckmann et al., 1991).
  • Efficacy: Lewis rats were immunized with recombinant vaccinia virus (VV) expressing various proteins of measles virus (MV). VVP (Phosphoprotein) -immunized rats were partially protected from MV challenge (Brinckmann et al., 1991).
References References References
Brinckmann et al., 1991: Brinckmann UG, Bankamp B, Reich A, ter Meulen V, Liebert UG. Efficacy of individual measles virus structural proteins in the protection of rats from measles encephalitis. The Journal of general virology. 1991; 72 ( Pt 10); 2491-2500. [PubMed: 1833505].
Brinckmann et al., 1991: Brinckmann UG, Bankamp B, Reich A, ter Meulen V, Liebert UG. Efficacy of individual measles virus structural proteins in the protection of rats from measles encephalitis. The Journal of general virology. 1991; 72 ( Pt 10); 2491-2500. [PubMed: 1833505].
Brinckmann et al., 1991: Brinckmann UG, Bankamp B, Reich A, ter Meulen V, Liebert UG. Efficacy of individual measles virus structural proteins in the protection of rats from measles encephalitis. The Journal of general virology. 1991; 72 ( Pt 10); 2491-2500. [PubMed: 1833505].